Kwality Pharmaceuticals Complete Financial Statements
In FY2026, Kwality Pharmaceuticals (KPL) reported revenue ₹158 Cr, net profit ₹25 Cr and EPS ₹24.39, with a net profit margin of 15.8% and ROE of 7.5%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Kwality Pharmaceuticals stock price NSE.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
KPL Revenue, Net Profit & EBITDA — Year-on-Year Growth
KPL YoY (Mar 2025 vs Mar 2026) — revenue +35.0%, net profit +66.7%, EBITDA +48.1%, expenses +31.1%. Review KPL earnings multiple to evaluate earnings-based valuation against sector peers.
KPL Income Statement — Revenue, EBITDA & Net Profit
Kwality Pharmaceuticals revenue ₹158 Cr, EBITDA ₹40 Cr, net profit ₹25 Cr, EPS ₹24.39 (2026) — net profit margin 15.8%. Explore KPL fundamental worth to estimate fundamental worth using multiple valuation models.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Jun 2021 | Dec 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 112 | 117 | 112 | 124 | 90 | 93 | 80 | 85 | 70 | 70 | 68 | 79 | 57 | 66 | 71 | 57 | 184 | 121 | 89 |
| Expenses | 118 | 86 | 90 | 87 | 94 | 70 | 78 | 63 | 67 | 54 | 74 | 54 | 61 | 40 | 48 | 52 | 41 | 100 | 73 | 64 |
| EBITDA | 40 | 26 | 27 | 25 | 30 | 20 | 14 | 18 | 18 | 16 | -4 | 14 | 17 | 17 | 18 | 18 | 16 | 84 | 49 | 25 |
| Operating Profit Margin % | 25.00% | 23.00% | 22.00% | 22.00% | 24.00% | 22.00% | 15.00% | 22.00% | 21.00% | 22.00% | -7.00% | 20.00% | 21.00% | 28.00% | 25.00% | 26.00% | 27.00% | 45.00% | 40.00% | 28.00% |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 5 | 4 | 3 | 3 | 4 | 3 | 2 | 3 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Profit Before Tax | 32 | 19 | 19 | 17 | 22 | 13 | 6 | 11 | 11 | 8 | -10 | 7 | 10 | 12 | 14 | 14 | 10 | 80 | 46 | 22 |
| Tax | 6 | 4 | 5 | 5 | 6 | 4 | 2 | 3 | 3 | 2 | -2 | 2 | 2 | 2 | 4 | 4 | 3 | 21 | 11 | 6 |
| Net Profit | 25 | 14 | 15 | 12 | 16 | 9 | 4 | 8 | 9 | 6 | -7 | 5 | 8 | 9 | 11 | 11 | 7 | 60 | 34 | 16 |
| Earnings Per Share (₹) | 24.39 | 13.60 | 13.95 | 11.49 | 15.42 | 8.15 | 4.08 | 8.04 | 8.21 | 5.99 | -7.23 | 5.10 | 7.39 | 8.82 | 9.97 | 9.99 | 6.82 | 57.33 | 32.96 | 15.20 |
KPL Balance Sheet — Assets, Liabilities & Shareholders' Equity
KPL total assets ₹592 Cr, total equity ₹332 Cr, total liabilities ₹ Cr (2026) — ROE 7.5%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 592 | 447 | 394 | 354 | 341 | 166 | 133 | 105 | 96 | 71 | 51 | 37 |
| Current Assets | 406 | 284 | 243 | 207 | 228 | 106 | 89 | 75 | 75 | 53 | 38 | 25 |
| Fixed Assets | 173 | 146 | 139 | 121 | 92 | 57 | 43 | 29 | 20 | 17 | 13 | 13 |
| Capital Work in Progress | 17 | 0 | 0 | 14 | 12 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 78 | 0 | 0 | 0 | 0 | 4 | 3 | 4 | 5 | 3 | 2 | 1 |
| Other Assets | 0 | 302 | 255 | 219 | 237 | 102 | 87 | 72 | 71 | 51 | 37 | 24 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 37 | 15 | 20 | 29 | 21 | 28 | 20 | 8 | 6 | 4 | 3 | 1 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 332 | 262 | 223 | 199 | 180 | 60 | 45 | 36 | 29 | 25 | 21 | 19 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 5 | 5 | 4 |
| Reserves & Surplus | 321 | 254 | 214 | 190 | 171 | 51 | 36 | 27 | 19 | 20 | 17 | 15 |
KPL Cash Flow Statement — Operating, Investing & Financing
Kwality Pharmaceuticals operating cash flow ₹53 Cr, investing ₹-29 Cr, financing ₹-14 Cr, net cash flow ₹10 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 53 | 43 | 41 | 61 | 27 | 6 | 14 | -1 | 4 | -3 | 1 |
| Investing Activities | -29 | -26 | -48 | -63 | -23 | -18 | -12 | -6 | -7 | -3 | -1 |
| Financing Activities | -14 | -17 | 1 | 6 | 1 | 12 | -2 | 5 | 5 | 6 | 1 |
| Net Cash Flow | 10 | -1 | -6 | 3 | 4 | 0 | 0 | -1 | 2 | 0 | 1 |